Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

NewsGuard 100/100 Score

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ.  

Approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, ARIDOL is the first new bronchial challenge test in more than two decades.  It is used for the assessment of bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma.  The easy-to-administer, single-use test, which delivers dry powder mannitol to the patient through a hand-held inhaler, can be conducted in a variety of healthcare settings including physician offices and pulmonary function labs.  ACAAI meeting attendees can preview ARIDOL and see a demonstration of how it works at the Pharmaxis booth #s1124 and 1126.

ARIDOL is an easy-to-administer, accurate and reproducible bronchial challenge test that requires minimal preparation and administration time.  A positive response is indicated when there is a 15% reduction in lung function from baseline.  

ARIDOL has been found effective and recognized as generally safe in two Phase III global clinical trials. It is widely recognized by experts as a significant addition to the tools available to help in an overall clinical assessment of asthma.  ARIDOL should not be used as a stand-alone tool to assess asthma, but as part of a physician's overall assessment of asthma.

SOURCE Pharmaxis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Project PROTECTS launches to track acute respiratory infections across the United States